Clinical trial · Interventional
Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation
Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation: a Clinical Study
NCT05460195CI-TRIAL-00059671unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To study the efficacy of sintilimab combined with anlotinib for perioperative non-small cell lung cancer. To explore the clearance effect of sintilimab combined with anlotinib for postoperative adjuvant therapy based on evaluating minimal residual disease.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anti-angiogenesis | — | UNRESOLVED | — |
| Immunotherapy | — | UNRESOLVED | — |
| Minimal Residual Disease | — | UNRESOLVED | — |
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| sintilimab combined with anlotinib | Drug | — | UNRESOLVED |
| sintilimab monotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Combination therapy group
- description
- Sintilimab combined with anlotinib
- interventionNames
- Drug: sintilimab combined with anlotinib
- type
- EXPERIMENTAL
- label
- Single-agent therapy group
- description
- Sintilimab monotherapy
- interventionNames
- Drug: sintilimab monotherapy
Primary outcomes (1)
- measure
- Major pathologic response (MPR)
- timeFrame
- 2 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cyologically confirmed stage II-IIIa NSCLC patients; * NSCLC patients with negative driver gene: EGFR wild-type, no ALK fusion mutation, no ROS1 fusion mutation; * ECOG PS: 0\~1; * Pulmonary function index meets the surgical criteria; * No previous systemic anti-tumor treatment. Exclusion Criteria: * Patients with central cavitary squamous cell carcinoma or investigator-assessed bleeding symptoms or bleeding tendency were excluded.
References
Publications (0)
Data not yet available
No reference posted for this study.